LLY Reports Third Phase III Win for Next-Generation Obesity Drug
Eli Lilly's retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader gains across obesity-related measures.
More News
HIMS Stock Extends 3-Day Rally: Hims & Hers Targets GLP-1 Gold Rush In Canada After Novo Nordisk Patent Expiry
The launch follows Novo Nordisk’s failure to pay a C$250 patent maintenance fee in Canada.
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting PR...
Eli Lilly's Triple Hormone Obesity Drug Shows Significant Weight Loss
Eli Lilly says retatrutide helped obesity trial participants lose up to 28.3% body weight in the Phase 3 TRIUMPH-1 study.read more...
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.
GSK Stock Declines 9% in a Month: Time to Buy, Hold or Exit?
GSK shares slide after Q1 despite earnings and sales beats, as investors weigh slowing legacy drug sales against strong Specialty Medicines growth.
Eli Lilly vs. Merck: Which Pharma Stock Looks Stronger Now?
LLY's booming GLP-1 franchise and expanding pipeline strengthen its edge over Merck despite rising competition and pricing pressure.
Could Viking Therapeutics Be the Next Eli Lilly?
Key PointsEli Lilly dominates the weight loss drug market and competes with fellow pharma giant Novo Nordisk...
Eli Lilly’s Retatrutide Delivers Bariatric-Style Weight Loss In Obesity Trial — Stock Rises Pre-Market
Eli Lilly said its retatrutide cleared a late-stage trial in patients with obesity, with some of them shedding a third of their body weight over 80 weeks.
Eli Lilly says next-generation weight loss drug clears crucial obesity trial
The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from existing injections and pills...